Nisa Investment Advisors’s CytomX Therapeutics CTMX Stock Holding History

Nisa Investment Advisors’s Portfolio CTMX Stock Details CTMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.94K	Buy	+518	New	+$1.98K	﹤0.01%	2756
2022 Q3	–	Sell	-1,245	Closed	-$2K	–	2589
2022 Q2	$2K	Hold	1,245	–	–	﹤0.01%	2342
2022 Q1	$3K	Hold	1,245	–	–	﹤0.01%	2330
2021 Q4	$6K	Hold	1,245	–	–	﹤0.01%	2074
2021 Q3	$6K	Hold	1,245	–	–	﹤0.01%	2246
2021 Q2	$8K	Hold	1,245	–	–	﹤0.01%	2246
2021 Q1	$10K	Hold	1,245	–	–	﹤0.01%	2208
2020 Q4	$8K	Buy	1,245 +550	+79%	+$3.93K	﹤0.01%	2236
2020 Q3	$5K	Hold	695	–	–	﹤0.01%	2194
2020 Q2	$6K	Buy	+695	New	+$6.45K	﹤0.01%	1993

Other funds holding CTMX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Nisa Investment Advisors's CTMX Position: Q2 2026 in Review

Nisa Investment Advisors opened a new position in CytomX Therapeutics (CTMX) in Q2 2026: 518 shares worth $1.94K. The stake represents ﹤0.01% of the portfolio and ranks #2756 among its holdings. This is a return to the name: Nisa Investment Advisors previously reported a position in CTMX as recently as Q2 2022.

Nisa Investment Advisors first reported a position in CTMX in Q2 2020 and has held it in 10 quarters since. The position peaked at $10K in Q1 2021. 178 funds tracked by Wall St. Rank hold CTMX as of Q2 2026.

Nisa Investment Advisors held 518 shares of CytomX Therapeutics worth $1.94K as of Q2 2026.
CytomX Therapeutics was a new Nisa Investment Advisors position in Q2 2026.
CytomX Therapeutics made up ﹤0.01% of Nisa Investment Advisors's portfolio in Q2 2026, its #2756 holding.
Nisa Investment Advisors first reported a position in CytomX Therapeutics in Q2 2020 and has held it in 10 quarters since.
Nisa Investment Advisors's CytomX Therapeutics position peaked at $10K in Q1 2021.
178 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2026.

Based on Nisa Investment Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.